HEPATOCELLULAR CARCINOMA AT INITIAL PRESENTATION AND ITS SUBSEQUENT THERAPEUTIC OPTIONS OFFERED: A TERTIARY CARE HOSPITAL EXPERIENCE

Objective: To determine the important clinical features at the initial presentation of Hepatocellular carcinoma and the treatments offered thereby. Study Design: Cross-sectional study. Place and Duration of Study: Department of Gastroenterology, Pak Emirates Military Hospital, Rawalpindi, from...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Asim Shehzad, Rabia Sajjad, Khawar Shabbir, Zafar Ali Qureshi, Farrukh Saeed, Abdullah Qamar
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2019
Materias:	hepatocellular carcinoma hepatitis c sorafenib Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/530f4c1cc1ab436baf6784953303fabe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:530f4c1cc1ab436baf6784953303fabe
record_format	dspace
spelling	oai:doaj.org-article:530f4c1cc1ab436baf6784953303fabe2021-11-10T02:34:03ZHEPATOCELLULAR CARCINOMA AT INITIAL PRESENTATION AND ITS SUBSEQUENT THERAPEUTIC OPTIONS OFFERED: A TERTIARY CARE HOSPITAL EXPERIENCE0030-96482411-8842https://doaj.org/article/530f4c1cc1ab436baf6784953303fabe2019-10-01T00:00:00Zhttps://www.pafmj.org/index.php/PAFMJ/article/view/3412/2387https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To determine the important clinical features at the initial presentation of Hepatocellular carcinoma and the treatments offered thereby. Study Design: Cross-sectional study. Place and Duration of Study: Department of Gastroenterology, Pak Emirates Military Hospital, Rawalpindi, from Jan 2017 to Dec 2017. Methodology: A total of 157 patients were studied. Their history, examination and relevant investigations were carried out at initial presentation to find all required details including age, gender, etiology of HCC, number and size of hepatic lesions, Child Pugh class, performance status, BCLC scoring, vascular invasion of tumor, lymph nodal involvement and metastasis; at time of diagnosis of hepatocellular carcinoma. Treatment was offered based on all these parameters, as per latest AASLD guidelines. Data were entered in SPSS version 24 for statistical analysis. Results: Of the total 157 patients, 117 (75%) were males and 40 (25%) were females. Mean age was 60.4 ± 8.67 years. Majority of HCC cases (84%) were HCV infected. Performance status was 0 or 1 in 87% cases. Around 52% patients had huge size of lesion, >5cm, at presentation. Child Pugh score was A for 68% patients. BCLC score was B, C or D in 70% cases which implies intermediate or advanced disease where curative treatments could not be performed. TACE was the most frequent treatment offered (33% cases), followed by Sorafenib (29% cases). Conclusion: Hepatocellular carcinoma was found to be on the rise in our setup as a consequence of the huge prevalence of HCV infection. Most patients were males presenting at intermediate or advanced stage disease where curative treatments were not possible.Asim ShehzadRabia SajjadKhawar ShabbirZafar Ali QureshiFarrukh SaeedAbdullah QamarArmy Medical College Rawalpindiarticlehepatocellular carcinomahepatitis csorafenibMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 69, Iss 5, Pp 1051-1056 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatocellular carcinoma hepatitis c sorafenib Medicine R Medicine (General) R5-920
spellingShingle	hepatocellular carcinoma hepatitis c sorafenib Medicine R Medicine (General) R5-920 Asim Shehzad Rabia Sajjad Khawar Shabbir Zafar Ali Qureshi Farrukh Saeed Abdullah Qamar HEPATOCELLULAR CARCINOMA AT INITIAL PRESENTATION AND ITS SUBSEQUENT THERAPEUTIC OPTIONS OFFERED: A TERTIARY CARE HOSPITAL EXPERIENCE
description	Objective: To determine the important clinical features at the initial presentation of Hepatocellular carcinoma and the treatments offered thereby. Study Design: Cross-sectional study. Place and Duration of Study: Department of Gastroenterology, Pak Emirates Military Hospital, Rawalpindi, from Jan 2017 to Dec 2017. Methodology: A total of 157 patients were studied. Their history, examination and relevant investigations were carried out at initial presentation to find all required details including age, gender, etiology of HCC, number and size of hepatic lesions, Child Pugh class, performance status, BCLC scoring, vascular invasion of tumor, lymph nodal involvement and metastasis; at time of diagnosis of hepatocellular carcinoma. Treatment was offered based on all these parameters, as per latest AASLD guidelines. Data were entered in SPSS version 24 for statistical analysis. Results: Of the total 157 patients, 117 (75%) were males and 40 (25%) were females. Mean age was 60.4 ± 8.67 years. Majority of HCC cases (84%) were HCV infected. Performance status was 0 or 1 in 87% cases. Around 52% patients had huge size of lesion, >5cm, at presentation. Child Pugh score was A for 68% patients. BCLC score was B, C or D in 70% cases which implies intermediate or advanced disease where curative treatments could not be performed. TACE was the most frequent treatment offered (33% cases), followed by Sorafenib (29% cases). Conclusion: Hepatocellular carcinoma was found to be on the rise in our setup as a consequence of the huge prevalence of HCV infection. Most patients were males presenting at intermediate or advanced stage disease where curative treatments were not possible.
format	article
author	Asim Shehzad Rabia Sajjad Khawar Shabbir Zafar Ali Qureshi Farrukh Saeed Abdullah Qamar
author_facet	Asim Shehzad Rabia Sajjad Khawar Shabbir Zafar Ali Qureshi Farrukh Saeed Abdullah Qamar
author_sort	Asim Shehzad
title	HEPATOCELLULAR CARCINOMA AT INITIAL PRESENTATION AND ITS SUBSEQUENT THERAPEUTIC OPTIONS OFFERED: A TERTIARY CARE HOSPITAL EXPERIENCE
title_short	HEPATOCELLULAR CARCINOMA AT INITIAL PRESENTATION AND ITS SUBSEQUENT THERAPEUTIC OPTIONS OFFERED: A TERTIARY CARE HOSPITAL EXPERIENCE
title_full	HEPATOCELLULAR CARCINOMA AT INITIAL PRESENTATION AND ITS SUBSEQUENT THERAPEUTIC OPTIONS OFFERED: A TERTIARY CARE HOSPITAL EXPERIENCE
title_fullStr	HEPATOCELLULAR CARCINOMA AT INITIAL PRESENTATION AND ITS SUBSEQUENT THERAPEUTIC OPTIONS OFFERED: A TERTIARY CARE HOSPITAL EXPERIENCE
title_full_unstemmed	HEPATOCELLULAR CARCINOMA AT INITIAL PRESENTATION AND ITS SUBSEQUENT THERAPEUTIC OPTIONS OFFERED: A TERTIARY CARE HOSPITAL EXPERIENCE
title_sort	hepatocellular carcinoma at initial presentation and its subsequent therapeutic options offered: a tertiary care hospital experience
publisher	Army Medical College Rawalpindi
publishDate	2019
url	https://doaj.org/article/530f4c1cc1ab436baf6784953303fabe
work_keys_str_mv	AT asimshehzad hepatocellularcarcinomaatinitialpresentationanditssubsequenttherapeuticoptionsofferedatertiarycarehospitalexperience AT rabiasajjad hepatocellularcarcinomaatinitialpresentationanditssubsequenttherapeuticoptionsofferedatertiarycarehospitalexperience AT khawarshabbir hepatocellularcarcinomaatinitialpresentationanditssubsequenttherapeuticoptionsofferedatertiarycarehospitalexperience AT zafaraliqureshi hepatocellularcarcinomaatinitialpresentationanditssubsequenttherapeuticoptionsofferedatertiarycarehospitalexperience AT farrukhsaeed hepatocellularcarcinomaatinitialpresentationanditssubsequenttherapeuticoptionsofferedatertiarycarehospitalexperience AT abdullahqamar hepatocellularcarcinomaatinitialpresentationanditssubsequenttherapeuticoptionsofferedatertiarycarehospitalexperience
_version_	1718440743913127936

HEPATOCELLULAR CARCINOMA AT INITIAL PRESENTATION AND ITS SUBSEQUENT THERAPEUTIC OPTIONS OFFERED: A TERTIARY CARE HOSPITAL EXPERIENCE

Ejemplares similares